Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RSLV-132
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Resolve Therapeutics Completes Enrollment of Phase 2 Long Covid Clinical Trial
Details : RSLV-132 is a safe, novel, targeted biologic drug designed to remove pro-inflammatory nucleic acids from the circulation of patients, which is one of the key triggers of multiple pro-inflammatory cascades.
Brand Name : RSLV-132
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 07, 2022
Lead Product(s) : RSLV-132
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : RSLV-132
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Based on previous positive phase 2 clinical trial with RSLV-132 in autoimmune fatigue, removing circulating RNA in long covid patients will have a similar improvement in their fatigue and brain fog.
Brand Name : RSLV-132
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 23, 2021
Lead Product(s) : RSLV-132
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : RSLV-132
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Resolve Therapeutics Publishes Positive Sjogren’s Syndrome Clinical Trial Results
Details : The Phase 2 study demonstrated a clinically meaningful improvement in four separate, independent, validated measures of fatigue in the RSLV-132 group, but not the placebo group.
Brand Name : RSLV-132
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 03, 2020
Lead Product(s) : RSLV-132
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?